Peculiarities of management of elderly patients with chronic cerebral ischemia
Mkhitaryan Elen Araikovna - PhD, Associate Professor of the Department of Aging Diseases of the Faculty of Continuing Professional Education of the Russian National Research Medical University named after N.I. Pirogov of the Ministry of Health of the Russian Federation, Head of the Laboratory of Neurogeriatrics of the Russian Scientific and Clinical Center
Evgeniya Viktorovna Yekusheva - MD, PhD, Professor, Head of the Department of Nervous Diseases and Neurorehabilitation of the Academy of Postgraduate Education of the Federal State Budgetary Institution Federal Scientific and Clinical Center of the Federal Medical and Biological Agency of Russia
Announcement:
One of the most common causes of cognitive impairment in elderly and senile patients is chronic cerebral ischemia (CCI). Given that many elderly patients believe that memory impairment and other cognitive functions are a manifestation of the normal aging process, such patients rarely complain of cognitive decline when visiting a doctor. The line between progressive moderate cognitive impairment and the initial stages of dementia is very thin. Therefore, it is extremely important to identify the moment of this transition in time and manage to adequately help the patient in time.
In everyday practice, various screening tests and scales are used to identify cognitive impairment, however, the number one scale in screening vascular cognitive impairment is the Montreal Cognitive Assessment Scale. According to clinical guidelines, diagnostics should be performed at the general therapeutic stage, after examination and diagnosis, the patient moves to the next stage - the treatment stage.
Pharmacotherapy of elderly patients is a complex task. First of all, it is extremely important to avoid polypharmacy when choosing a drug.
Mexidol® is a multimodal neurocytoprotector, the combination of effects of the drug Mexidol® allows to influence the main clinical symptoms of cerebrovascular pathology, avoiding additional prescription of drugs due to the multimodality of its effects, improving patient compliance to treatment and increasing the safety of pharmacotherapy.